Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani
6.9.2024 21:41:00 EEST | Business Wire | Press release
Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/
Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire)
After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe Kiani with the deepest respect from the global community of families, experts, policymakers, and politicians in patient safety who have greatly benefited from his unwavering commitment to reducing avoidable harm to zero. His partnership with the World Health Organization, his contribution to the Global Patient Safety Action Plan, his outstanding leadership over many years at the Global Ministerial Summits on Patient Safety, and his drive and determination to ensure the ongoing advancement of science and technology across the global medical devices industries have ensured that our patients at every level and in every setting continue to benefit from his latest advances to reduce avoidable harm. The healthcare world is a safer environment because of his dedication, and both patients and healthcare workers will continue to reap the benefits of his excellence for decades to come.”
“I’m honored,” stated Joe Kiani. “The Patient Safety Global Ministerial Summit, the World Health Organization, and Dr. Tedros Adhanom Ghebreyesus have played a leading role in making patient safety a priority around the world. I believe that if we all work together, we have the tools and know-how to create a safer healthcare system for all. To get to zero, we have to implement evidence-based practices, and we need our board members and hospital C-suites demanding their implementation. There is great momentum, and we cannot stop until we reach ZERO preventable harm in our hospitals.”
Since their inception in 2016, the Global Ministerial Summits on Patient Safety have succeeded in raising awareness, as well as creating and sustaining the momentum of the global patient safety movement, as evidenced by the adoption of the WHA resolution (WHA72.6) “Global Action on Patient Safety” in May 2019, which enabled the first-ever World Patient Safety Day in September 2019.
Some of the world’s most prominent leaders in patient safety are presenting at the PSMF’s Summit this year, including Dr. Don Berwick, Senior Fellow at the Institute for Healthcare Improvements. In his keynote, Berwick will discuss how to ensure progress on improvements in patient safety remain at the forefront of the national conversation following last year’s recommendations to the US president in the PCAST report, “A Transformational Effort on Patient Safety.”
During the afternoon session, Dr. Craig Umscheid, Director of the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality (AHRQ), will speak on AHRQ’s National Action Alliance for Patient and Workforce Safety, which takes a systems approach informed by safety self-assessments to improve patient and workforce safety across all healthcare delivery settings, with a goal of reducing harms by 50% from the pandemic peak in two years.
In her keynote, Dr. Michelle Schreiber, Director of Quality Measurement & Value Based Incentives Group, Center for Medicare and Medicaid Services (CMS), will detail the eight goals of CMS’s National Quality Strategy and outline CMS’s efforts to improve healthcare for all by promoting transparency and a safety culture through partnerships, while incentivizing zero harm.
The Summit’s first day will also include presentations from Dr. Diana Ramos, the Surgeon General of California; Dr. Peter Ziese, Head of Medical Innovation & Strategy at PHILIPS; Scott Hamilton Kennedy, an Academy Award-nominated documentary filmmaker; Dr. Evan Benjamin, Associate Professor of Medicine at Harvard Medical School; and Henrietta Hughes, the Patient Safety Commissioner for England.
Panel discussions will focus on advancements in using real-time data from electronic medical records, improving safety through systemwide collaboration, and the essential role hospital boards and the C-suite can play in fostering a culture of safety.
PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906604830/en/
Contacts
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom